Last reviewed · How we verify
NCT07517250
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
trial in Familial Mediterranean Fever in 160 participants. Not yet recruiting.
21 September 2026
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 7 April 2026 |
| Primary completion | 21 September 2026 |
| Estimated completion | 21 September 2026 |
Conditions studied
- Familial Mediterranean Fever — all drugs for Familial Mediterranean Fever →
- Still Disease — all drugs for Still Disease →
- Systemic Juvenile Idiopathic Arthritis — all drugs for Systemic Juvenile Idiopathic Arthritis →
- Adult-Onset Still Disease — all drugs for Adult-Onset Still Disease →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
1 and older, any sex, with Familial Mediterranean Fever or Still Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07517250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Familial Mediterranean Fever
Currently open trials in the same condition.
- NCT07129538 — Outcomes of Inspiratory Muscle Training in FMF Adolescents · NA · recruiting
- NCT07130305 — is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT07128225 — Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever · active not recruiting
- NCT06338891 — Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07517250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07517250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing